Ambu A/S (OTCMKTS:AMBBY – Get Free Report) and Avita Medical (NASDAQ:RCEL – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Profitability
This table compares Ambu A/S and Avita Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ambu A/S | 8.18% | 8.49% | 6.75% |
| Avita Medical | -56.96% | N/A | -78.53% |
Earnings & Valuation
This table compares Ambu A/S and Avita Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ambu A/S | $894.37 million | 3.06 | $90.19 million | $0.30 | 38.80 |
| Avita Medical | $71.61 million | 5.65 | -$48.59 million | ($1.44) | -9.12 |
Ambu A/S has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
27.7% of Avita Medical shares are held by institutional investors. 2.2% of Avita Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Ambu A/S and Avita Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ambu A/S | 0 | 1 | 0 | 0 | 2.00 |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
Avita Medical has a consensus price target of $12.20, indicating a potential downside of 7.15%. Given Avita Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Avita Medical is more favorable than Ambu A/S.
Volatility and Risk
Ambu A/S has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
About Ambu A/S
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
